Hero Finding
Shown the story blind, 79% of executives said it reflects what happens inside their own organization; only 3% said it does not reflect them at all.
Recognition was strongest exactly where the campaign needs it: half of finance chiefs and 44% of supply chain chiefs said the story reflects their organization very closely. Beneath the recognition sits a real deficit: only 15% of executives were extremely confident that negotiated savings ultimately show up in financial performance.
How closely the story reflects the respondent's own organization · share of all 62 executives · fielded blind with no sponsor reveal and no leading language
Key Findings
What the blind test surfaced.
Six signals shaped the launch read, each grounded in the same 62 executives' scaled measures and unaided language.
The narrative cleared a deliberately hostile test: 79% of executives recognized their own organization in it.
The AI moderator ran every session under an explicit rule: ask whether and how the gap shows up, never imply that it exists, and never reveal a sponsor. Under those conditions, 32% of executives said the spend-performance story reflects their organization very closely and 47% somewhat closely; only 3% said it does not reflect them at all. Recognition peaked with the seats the campaign reaches first, finance chiefs (half said very closely) and supply chain chiefs (44% very closely).
Confidence that negotiated savings reach the P&L is thin: 15% of executives are extremely confident.
Just 3% said value does not meaningfully break down between the original opportunity and the financial result. In the open ends, executives described savings that are negotiated cleanly and then erode through utilization shifts, substitutions, and limited follow-up before they reach the financial statements. The deficit the narrative names is confirmed here at the buying committee's own admission.
The leak points executives name concentrate after the contract is signed.
Asked where value most commonly breaks down, executives converged on off-contract buying (44%) and clinical or product variation (44%), followed by implementation gaps (40%), manual reconciliation (35%), and fragmented data (32%). These are lifecycle-execution failures, which is precisely the framing the narrative advances.
No single function owns realization: the top answer, finance, stops at 34%.
Asked which function is primarily accountable for ensuring identified savings reach the P&L, finance led at 34%, supply chain followed at 27%, and the remainder scattered across five other functions. A problem the whole committee recognizes and no one clearly owns is natural territory for an orchestration partner, and the data documents that vacancy in the buyers' own answers.
The three concepts read as one approach, and the leading concept depends on the seat.
94% of executives saw the three solution concepts as at least somewhat connected parts of one approach, with 66% calling them clearly connected. Clinically integrated supply chain led forced-choice relevance at 42%, ahead of tail-spend automation (27%) and purchase-to-pay price assurance (24%); only 6% found none relevant. Operations chiefs broke two-to-one for clinical integration (10 of 15, tested significant against supply chain chiefs), while supply chain chiefs leaned toward tail-spend automation (8 of 18).
The diagnostic entry offer cleared decisively: 90% called it appealing and zero rejected it outright.
A low-commitment diagnostic benchmarking negotiated savings against what actually reached the P&L was rated very appealing by 63% of executives and somewhat appealing by 27%; not a single respondent chose not at all appealing. Appeal concentrated among executives who bought the connected story, confirming the intended sequence: the narrative earns the diagnostic, and the diagnostic opens the account. The validation arrived from six days of blind fielding, before launch spend was committed.
It is the delta between what we've identified as an opportunity and what we actually achieve.
Chief Supply Chain Officer · Integrated Delivery Network
Study Design
N=62senior health system executives
52 of 62 C-suite
Fully blind protocol
Quant + qual in one instrument
Fielded 28 July to 3 August, six days in field, under a moderation rule that asked whether and how the gap shows up without ever implying it exists. Functional quotas held a readable base for every seat on the buying committee. Respondents defined the story and each concept in their own words before rating anything, separating genuine comprehension from polite agreement, and logical-consistency flags routed contradictory confidence answers to human review before the base locked. Every reaction measure was significance-tested across more than fifteen segment banners.
Sample by segment
Mix
What the guide covered
- Confidence that negotiated savings ultimately reach financial performance, and what shapes it
- Where value most commonly breaks down between the original opportunity and the financial result
- Accountability for savings realization across the executive team
- Unaided interpretation of the spend-performance story, exposed with no sponsor attached
- Staged reaction to three concepts: tail-spend automation, purchase-to-pay price assurance, clinically integrated supply chain
- Cross-concept connectedness and forced-choice relevance by executive seat
- Appeal of a low-commitment diagnostic as a first step, and what buyers need before agreeing
Who qualified
- VP and above at U.S. provider organizations; 52 of 62 C-suite
- Direct decision involvement in supply chain strategy, spend management, margin improvement, or savings realization
- 43 of 62 the final decision-maker for spend-management investments
- Functional quota cells across supply chain and procurement, finance, operations, and enterprise strategy
Crosstab · Concept Relevance
Clinical integration leads concept relevance at 42%, and the leader flips by executive seat.
Forced-choice relevance across all 62 executives, with the two seat-level reads the study stat-tested. Operations chiefs concentrate on clinical integration; supply chain chiefs tilt toward tail-spend automation. Cells the study did not report are marked with an en-dash.
| All executives (n=62) | Operations chiefs (n=15) | Supply chain chiefs (n=18) | |
|---|---|---|---|
| Clinically integrated supply chain | 42% | 10 of 15 | – |
| Tail-spend automation | 27% | – | 8 of 18 |
| Purchase-to-pay price assurance | 24% | – | – |
| None feel especially relevant | 6% | – | – |
Ops chiefs two-to-one for clinical integration · stat-tested vs supply chain chiefs · 94% see the three concepts as one connected approach · n=62
Voice of Customer
What health system executives actually said.
Verbatim excerpts from the blind sessions, selected to span the buying committee's seats and tied to the findings above.
“The contract gets signed. Everybody gets excited. We're all gonna move to a particular item. That item's gonna save us you know, $100 every time it gets used. It's supposed to get used a thousand times a year. And for some reason, we don't see that utilization, so the savings doesn't materialize.”
“We're always spending time chasing down vendors, looking at what those discrepancies are, and it's very time consuming from our buyer standpoint and from our AP standpoint.”
“And sometimes it takes a village to be able to do a deep dive analysis and to find out where the controls are, where the missteps are.”
“We currently have 5 hospitals in our hospital system, and each hospital uses different supplies.”
“How long would this take, and how much would it cost and what's the return on investment?”
Implications · what the evidence supports
Four readings from the research.
What the campaign team took into launch planning, grounded in the blind read.
The narrative is launch-grade with the committee it targets.
79% recognition under a protocol built to let the story fail is the strongest pre-launch evidence available that the framing will land in market. Recognition peaks with finance and supply chain chiefs, the seats the campaign reaches first, and only 3% said the story does not reflect their organization at all.
The proof-point hierarchy follows the leak points executives name most.
Off-contract buying and clinical or product variation lead the breakdown map at 44% each, with implementation gaps, manual reconciliation, and fragmented data behind them. The breakdown map doubles as a proof-point order for campaign copy, in the language buyers used unaided.
The ownership vacancy is the positioning territory, and concept emphasis maps role by role.
No function claims realization accountability above 34%, which leaves the orchestration ground unoccupied at the committee's own admission. Clinical integration carries operations audiences, tail-spend automation carries supply chain audiences, and the connected-approach frame holds the three together for 94% of the sample.
The diagnostic is the validated first ask, sequenced after the story.
90% appeal with zero outright rejection clears the entry offer's bar before launch spend was committed. Appeal concentrated among executives who read the three concepts as one approach, which confirms the intended sequence: the narrative earns the diagnostic, and the diagnostic opens the account.
Signals the data flagged
- 79% of executives recognize their own organization in a blind-tested story
- Zero of 62 rejected the diagnostic entry offer outright
- 94% read the three concepts as one connected approach
- No function claims savings-realization accountability above 34%
Risks the data surfaced
| Ownership vacancy leaves no natural budget owner for a realization deal | High |
| One lead concept misses seats: relevance flips between operations and supply chain | Med |
| Single-phase read: message wear over time is unmeasured | Med |
| 10% found the diagnostic not very appealing | Low |